EDN1 and cancer: Furthermore, it has been alluded to that macitentan can interfere with the β-arr1 signalling network by blocking the ET-1 receptors, preventing ET-1 signalling and improving the response of cancer cells to platinum-based chemotherapy, as well as downregulating angiogenesis and metastatic action in different cancer types [17,18].